Program
- Day 1 - October 27, 2022
- Day 2 - October 28, 2022
- Day 3 - October 29, 2022
- Day 4 - October 30, 2022
- Download Program
Thursday, October 27, 2022
[8:00-9:15] Session I
WM Predisposition
Mary McMaster, Alessandra Trojani [Chairs]
GWAS Study Findings in Familial Plasma Cell Dyscrasias incl. WM
Mary McMaster, National Institutes of Health, USA
Clonal Lymphopoiesis and predisposition to WM
Bruno Paiva, University of Navarra, Spain
Common gene set signature in IGM MGUS and WM by transcriptome analysis
Alessandra Trojani, Ospedale Metropolitano Niguarda, Italy
Twin Genomic Studies in WM: Identification of FHL2 Gene Mutation
Jian Hou, Renji Hospital, Shanghai Jiao Tong University, China
Clonal Hematopoiesis and risk of WM Progression
Adam Sperling, Dana Farber Cancer Institute, USA
[9:15-10:45] Session II
WM Genomics I
Bruno Paiva, Zachary Hunter [Chairs]
Comprehensive WES Study of WM-300 project
Zachary Hunter, Dana Farber Cancer Institute, USA
Genomic differences of CXCR4 wild-type and mutated clones
Cristina Jimenez, University of Salamanca, Spain
Integration of cytogenetic and molecular screening for first line patients
Damien Roos-Weil, Hôpital Pitié-Salpêtrière, France
Genomic Variants in Chinese Patients with WM
Shuhua Yi, Tianjin Medical Center, China
Lon Non-Coding RNA Expression in IGM MGUS and WM
Jonas Paludo, Mayo Clinic, USA
Single Cell Analysis of MYD88 mutated and wild-type WM
Tina Bagratuni, University of Athens, Greece
[10:45-11:15] Morning Break
[11:15-12:45] Session III
WM Genomics II
Marzia Varettoni, Nikhil Munshi [Chairs]
DNA Methylation Profiling in WM
Damien Roos-Weil, Hôpital Pitié-Salpêtrière, France
Epigenomic Regulation by ATAC Seq
Zachary Hunter, Dana Farber Cancer Institute, USA
Genomic studies in WM: first results from the BIOWM study of Fondazione Italiana Linfomi (FIL)
Marzia Varettoni, University of Pavia, Italy
Distinct Genomic Profile Characterizes IGM MM from WM
Nikhil Munshi, Dana Farber Cancer Institute, USA
Genomic Landscape of WM reveals late developing CAN
Kylee MacLachlan, Memorial Sloan Kettering Cancer Center, USA
Proteomic and Metabolomic Studies in WM
Shahrzad Jalali, Mayo Clinic, USA
[12:45-13:45] LUNCH
[13:45-14:15] Keynote Lectures
What the genomics of WM tells us about its curability
Keynote Speaker: Steven Treon, Dana Farber Cancer Institute, USA
Targeting the Epigenome: Opportunities for WM
Keynote Speaker: Ari Melnick, Cornell University, USA
[14:15-15:45] Session IV
Transgenic Models for WM
Ruben Carrasco, Jose Martinez-Climent, [Chairs]
MYD88 Transgenic Model
Klaus Rajewsky, Max Delbrück Center for Molecular Medicine, Germany
MYD88 L265P Transgenic Model
Ruben Carrasco, Dana Farber Cancer Institute, USA
Unraveling and targeting the immune microenvironment in MYD88 lymphomas
Jose Martinez-Climent, University of Navarra, Spain
Continuous activation of mutated MYD88
Christelle Vincent-Fabert, UMR CNRS/INSERM, France
CXCR4 Transgenic Model
Karl Balabanian, Inserm Unité Mixte de Recherche S996, France
TBL1XR1 Transgenic Model
Ari Melnick, Cornell University, USA
[15:45-16:15] Afternoon Break
[16:15-17:30] Session V
Signalomics in WM
Irene Ghobrial, Aldo Roccaro [Chairs]
MYD88 driven HCK pro-survival signaling
Guang Yang, Dana Farber Cancer Institute, USA
Mutated MYD88 related Ubiquitination
Yong Li, Baylor College of Medicine, USA
ERK dysregulation mediated by aberrant WNK2 expression
Maria Luisa Guerrera, Dana Farber Cancer Institute, USA
FGF/FGF-R Axis in MYD88 Mutated WM
Aldo Roccaro, ASST Spedali Civili di Brescia, Italy
Genomic evolution of ibrutinib resistant clones
Cristina Jimenez, University of Salamanca, Spain
[17:30] Day Adjournment
[18:00] Poster Presentations & Dinner Reception
Presentation of Young Investigator Awards
Presentation of Robert A. Kyle Award
Friday, October 28, 2022
[7:30-9:00] Session VI
Prognostic and Predictive Markers
Prashant Kapoor, Efstathios Kastritis, [Chairs]
Models-Risk Stratification of Asymptomatic WM
Romanos Sklavenitis-Pistofidis, Dana Farber Cancer Institute, USA
Predictors of Short Survival in WM
Prashant Kapoor, Mayo Clinic, USA
Impact of 6q on WM clinical outcomes
Ramon Garcia-Sanz, University of Salamanca, Spain
Clinical Response Predictors for BTK-I
Jithma Abeykoon, Mayo Clinic, USA
CXCR4 subtype and clonality impact ibrutinib response
Joshua Gustine, Dana Farber Cancer Institute, USA
Prognostic Impact of MYD88 L265P by ddPCR
Carlos Fernandez de Larrea, Hospital Clinic Barcelona, Spain
[9:00-9:30] Morning Break
[9:30-11:15] Session VII
Chemoimmunotherapy
Veronique Leblond, Luigi Qiu [Chairs]
B-RCD vs. RCD Randomized Trial in WM
Pierre Morel, Centre Hospitalier Universitaire Amiens Picardie, France
RCD vs BCD Randomized Trial
Lugui Qiu, National Clinical Research Center for Blood Diseases, China
Bendamustine/Rituximab: Dose Intensity and Patient Outcomes
Suzanne Arulogun, UC London Hospitals NHS, UK
FILO Bendamustine Rituximab
Veronique Leblond, Hôpital Pitié Salpêtrière, France
HOVON 124: Ixazomib, Dex., Rituximab in Previously Treated WM
M.J. Kersten, University of Amsterdam, Netherlands
STIL Maintenance Rituximab
Mathias Rummel, University of Giessen, Germany
BRB: Bendamustine, Rituximab, Bortezomib Study: Fondazione Italiana Linfomi Study
Giulia Benevolo, University of Torino, Italy
[11:15-11:45] Keynote Lectures
Benda or BTK-I for frontline WM treatment: Insights from CLL SEQUOIA Trial
Keynote Speaker: Constantine Tam, Peter MacCallum Cancer Centre, Australia
Mechanistic Insights into Adverse Events underlying BTK-inhibitors
Keynote Speaker: C.I. Edvard Smith, Karolinska Institut, Sweden
[11:45-12:45] LUNCH
[12:45-14:30] Session VIII
BTK-Inhibitors I
Judith Trotman, Meletios Dimopoulos [Chairs]
Long Term Follow-Up of Ibrutinib Monotherapy in Previously Treated WM
Steven Treon, Dana Farber Cancer Institute, USA
INNOVATE C/Update
Meletios Dimopoulos, University of Athens, Greece
Long Term Follow-Up of Ibrutinib Monotherapy in Frontline WM
Jorge Castillo, Dana Farber Cancer Institute, USA
Long Term Follow-up-INNOVATE A/B
Christian Buske, University Hospital Ulm, Germany
Real World Experiences with Ibrutinib-US experience
Jithma Abeykoon, Mayo Clinic, USA
Real World Experiences with Ibrutinib-UK experience
Shirley D’Sa, UC London Hospitals NHS, UK
Real World Data on CIT and BTK-inhibitors: WHIMSICAL Study
Ibrahim Tohidi-Esfahani, University of Sydney, Australia
[14:30-15:45] Session IX
BTK-Inhibitors II
Alessandra Tedeschi, Constantine Tam, [Chairs]
Long Term Follow-up-Acalabrutinib Phase II
Roger Owen, Leeds Hospital NHS Trust, UK
Long Term Follow-Up Zanubrutinib-Phase II
Judith Trotman, University of Sydney, Australia
Phase II Zanubrutinib in relapsed/refractory WM: Chinese experience
Lugui Qui, National Clinical Research Center for Blood Diseases, China
Long Term Follow-up-ASPEN
Constantine Tam, Peter MacCallum Cancer Centre, Australia
Long Term Follow-Up of Zanubrutinib in MYD88 WT WM
Meletios Dimopoulos, University of Athens, Greece
[15:45-16:15] Afternoon Break
[16:15-17:30] Session: X
Management of BTK-inhibitor exposed patients
Shayna Sarosiek, Carlos De Larrea [Chairs]
Dose reduction of ibrutinib and impact on treatment course
Shayna Sarosiek, Dana Farber Cancer Institute, USA
Zanubrutinib in patient’s intolerant to ibrutinib/acalabrutinib
Mazyar Shadman, Fred Hutchinson Cancer Res Center, USA
Venetoclax in Previously Treated WM incl. BTK-inhibitor exposed patients
Jorge Castillo, Dana Farber Cancer Institute, USA
Pirotbrutinib in Previously Treated WM Patients with Covalent BTK-inhibitor
- L. Palomba, Memorial Sloan Kettering Cancer Center, USA
MK-1026 Dose Expansion Study in B-cell malignancies incl WM
Deborah Stephens, University of Utah, Huntsman Cancer Institute, USA
[17:30] Day Adjournment
[18:30] Faculty Dinner Reception
Saturday, October 29, 2022
[7:30-10:15] Session XI
Great Debates in WM
Eva Kimby, Jesus San Miguel [Chairs]
[7:30-8:00] Great Debate I
Should we treat smoldering WM? -No
Prashant Kapoor, Mayo Clinic, USA
Should we treat smoldering WM? -Yes
Irene Ghobrial, Dana Farber Cancer Institute
[8:00-8:30] Great Debate II
Should BTK-I or Benda-R be the standard frontline induction regimen? -for Benda-R
Christian Buske, University Hospital Ulm, Germany
Should BTK-I or Benda-R be the standard frontline induction regimen? -for BTK-I
Meletios Dimopoulos, University of Athens, Greece
[8:30-9:15] Great Debate III
Does the choice of BTK-inhibitor matter? -for Ibrutinib
Ranjana Advani, Stanford University Medical Center, USA
Does the choice of BTK-inhibitor matter? -for Acalabrutinib
Roger Owen, Leeds Hospital NHS Trust, UK
Does the choice of BTK-inhibitor matter? -for Zanubrutinib
Judith Trotman, University of Sydney, Australia
[9:15-9:45] Great Debate IV
Managing the ibrutinib intolerant patient: Dose reduce or switch to another BTK-inhibitor? -Dose reduce
M Lia Palomba, Memorial Sloan Kettering Cancer Center, USA
Managing the ibrutinib intolerant patient: Dose reduce or switch to another BTK-inhibitor? -Switch
Alexandra Tedeschi, Niguarda Hopital, Italy
[9:45-10:15] Great Debate V
What should be the end point of therapy in WM? -Disease control should be the endpoint of therapy
Stathis Kastritis, University of Athens, Greece
What should be the end point of therapy in WM? -CR should be the endpoint of therapy
Jorge Castillo, Dana Farber Cancer Institute, USA
[10:15-10:45] Morning Break
[10:45-11:45] Session XII
Novel Treatment Approaches to WM-Clinical I
Sheeba Thomas, Moshe Gatt [Chairs]
Venetoclax in combination with ibrutinib for WM
Jorge Castillo, Dana Farber Cancer Institute, USA
Targeting mutated CXCR4 in WM
Steven Treon, Dana Farber Cancer Institute, USA
Obinutuzumab and Idelalisib in WM
Veronique Leblond, Hôpital Pitié Salpêtrière, France
Acalabrutinib and Rituximab for WM and IGM RD PN
Shayna Sarosiek, Dana Farber Cancer Institute, USA
[11:45-12:30] Session XIII
Novel Treatment Approaches to WM-Clinical II
Jorge Castillo, Stephen Ansell [Chairs]
Tirabrutinib in Treatment Naïve and Prev Treated WM-Phase II
Koji Izutsu, National Cancer Center Hospital, Japan
Phase II study of Orelabrutinib in relapsed/refractory WM
Xinxin Cao, Peking Union Medical College, China
Clinical Activity of IRAK4 Inhibitor CA-4948 in NHL, incl. WM
Reinhard Von Roemeling, Curis Pharmaceuticals, USA
[12:30-13:30] LUNCH
[13:30-14:30] Session XIV
Novel Treatment Approaches to WM-Clinical III
Merav Leiba, Shirley D’Sa [Chairs]
Bispecifics in WM-CD3XCD20 RGN1979
Stephen Ansell, Mayo Clinic, USA
Phase II Study of Loncastuximab in WM
Shayna Sarosiek, Dana Farber Cancer Institute, USA
Idiotype DNA Vaccine Therapy for WM
Sheeba Thomas, MD Anderson, USA
CD20 CAR-T therapy for WM and other B-NHLs
Mazyar Shadman, Fred Hutchinson Cancer Res Center, USA
[14:30-15:00] Keynote Lectures
Bi-specifics and Conjugated Antibodies: MM Experience
Keynote Speaker: Kenneth C. Anderson, Dana Farber Cancer Institute, USA
Bringing CART to WM: Which One?
Keynote Speaker: Nikhil Munshi, Dana Farber Cancer Institute, USA
[15:00-15:30] Afternoon Break
[15:30-16:30] Session XVI
Plenary
Veronique Leblond, Jésus San Miguel [Chairs]
Presentation 1
TBD
Presentation 2
TBD
Presentation 3
TBD
Presentation 4
TBD
[16:30-17:15] Session XVII
Special Topics Lectures
Clinical Characteristics and Outcomes with Cryoglobulinemia in WM
Speaker: Shirley D’Sa, UC London Hospitals NHS, UK
Clinical Characteristics and Outcomes with Cold Agglutinins in WM
Speaker: Josephine Vos, University of Amsterdam, Netherlands
Management of Amyloidosis in WM Patients
Speaker: Giampaolo Merlini, University of Pavia, Italy
[17:15] Day Adjournment
[19:30] Dinner Reception & Closing Ceremonies
Presentation of Peter S. Bing Humanitarian Awards
Presentation of Jan Gosta Waldenstrom Awards
Sunday, October 30, 2022
[9:00] Keynote Lectures
Challenges of COVID in WM Patient Care
Keynote Speaker: Meletios Dimopoulos, University of Athens, Greece
[9:15-10:30] Session XV
COVID and WM
Ramon Garcia Sanz, Andrew Branagan [Chairs]
Responses to COVID vaccination in WM and MM Patients
Andrew Branagan, Massachusetts General Hospital, USA
Responses to COVID vaccination (initial and booster dose) in patients with plasma cell neoplasms
Evangelos Terpos, University of Athens, Greece
GETH-TC Study on Serological responses to initial vaccination and booster in heme patients
with /without prior COVID19
Ramon Garcia-Sanz, University of Salamanca, Spain
Efficacy of BNT162b2 in WM and FLL -Australian Experience
Judith Trotman, University of Sydney, Australia
Impact of Booster Vaccination on SARS-COV-2 Antibody Levels in Blood CA Patients incl. WM
Lee Greenberger, Leukemia Lymphoma Society (LLS), USA
[10:30] Day Adjournment
[10:30-11:00] Morning Break
[11:00-1:00] Panel Discussions
WM Management I
WM Consensus Panel I Report
IWWM-11 Recommendation for Treatment Approach in WM-Frontline
Organizers: Christian Buske, Jorge Castillo, Judith Trotman
WM Consensus Panel II Report
IWWM-11 Recommendation for Treatment Approach in WM-Relapsed/Refractory
Organizers: Efstathios Kastritis, Shirley D'SA, Jeffrey Matous
WM Consensus Panel III Report
IWWM-11 Recommendation for Molecular Diagnostic Workup in WM
Organizers: Ramon Garcia-Sanz, Marzia Varettoni, Zachary Hunter
WM Consensus Panel IV Report
Response Criteria for WM
Organizers: Steve Treon, Roger Owen, Alessandra Tedeschi
[13:00-14:00] LUNCH
[14:00-15:30] Panel Discussions
WM Management II
WM Consensus Panel V Report
COVID Prophylaxis and Management in WM
Organizers: Meletios Dimopoulos, Veronique LeBlond, Andrew Branagan
WM Consensus Panel VI Report
Management of WM-related Amyloidosis
Organizers: Monique Minnema, Shayna Sarosiek, Giampaolo Merlini
WM Consensus Panel VII Report
Priorities for Novel Clinical Trials
Organizers: MJ Kersten, Prashant Kapoor, Constantine Tam